Impact of Sacubitril–Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction

Introduction Sacubitril/valsartan (S–V) has been shown to reduce clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). This benefit has been mostly attributed to an improvement in systolic function. Aim This study aimed to evaluate longitudinal changes in several e...

Full description

Saved in:
Bibliographic Details
Published in:High blood pressure & cardiovascular prevention 2021-03, Vol.28 (2), p.167-175
Main Authors: Pericas, Pere, Mas-Lladó, Caterina, Ramis-Barceló, Maria Francisca, Valadrón, Isabel, Noris Mora, Marta, Pasamar Márquez, Lucía, González Colino, Rosa, Forteza Albertí, José Francisco, Peral Disdier, Vicente, Rossello, Xavier
Format: Article
Language:English
Subjects:
Angioedema
Cardiology
Cardiomyopathy
Cardiovascular disease
Doppler effect
Ejection fraction
Health risks
Heart failure
Ischemia
Longitudinal studies
Medical diagnosis
Medicine
Medicine & Public Health
Mortality
Original Article
Patients
Pharmacotherapy
Population
Software
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Sacubitril/valsartan (S–V) has been shown to reduce clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). This benefit has been mostly attributed to an improvement in systolic function. Aim This study aimed to evaluate longitudinal changes in several echocardiographic parameters of diastolic function in a cohort of patients with HFrEF receiving S–V. Methods Echocardiographic parameters of consecutive patients receiving S–V, such as diastolic dysfunction (DD) grade and other individual diastolic and systolic function parameters, were prospectively collected at baseline and at 6-month follow-up. New York Heart Association (NYHA) functional class was also recorded. Results 65 patients (73.9% males; 61.5 ± 13 years) with HFrEF in NYHA class II–IV were evaluated. There was a significant reduction in DD grade after treatment with maximal tolerated doses ( p 
ISSN:1120-9879
1179-1985
DOI:10.1007/s40292-021-00437-x